Bone Biologics Corp

Industrial Specialties company

📍 United States NASDAQ BBLG Pharmaceuticals & Healthcare

Search companies

Key Metrics of Bone Biologics Corp

Revenue₹7,818 Cr▲ 2.4% YoYFY 2020-21

EBITDA−₹13.3 Cr▲ 23.8% YoY

Net profit−₹13.3 Cr▲ 45.5% YoY

Net worth−₹100 Cr▼ 18.1% YoY

Market cap$1.2MBBLG · $0.35

Competitors10identified

About Bone Biologics Corp

Sectors

Pharmaceuticals & HealthcareBiotechnology & Vaccines

Company details

Listed: Nasdaq: BBLG

Operational Areas of Bone Biologics Corp

Pharmaceuticals & Healthcare›Biotechnology & Vaccines

Company summary

Legal nameBone Biologics Corp

TickerBBLG

ExchangeNasdaq

CountryUnited States

SEC CIK0001419554

Listed since—

IndustryIndustrial Specialties

SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines

Website—

US market & SEC filings

BBLG · Nasdaq · SEC CIK 0001419554

Last price · 04 Nov 2026 $0.35 −4.69%

Market cap$1.2M

P/E—On FY 2023 diluted EPS

Volume37,934

SectorHealth CareIndustrial Specialties

Country · IPOUnited States

BBLG share price

Premium

Annual results (SEC EDGAR)

Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Vendor checks & payment capacity

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Consolidated accounts · FY 2020-21

Indicative long-term—

Indicative short-term—

Score—

LiquidityNot assessable

DirectionStable

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

Default	No default on record
Issuer cooperation	Cooperating
Credit enhancement	None – standalone rating
Information on file	22% · missing: Audited financial statements (last 18 months), Liquidity position, Capex / investment plans, Lender details, Auditor details, Shareholding pattern, Recent rating review (last 15 months)

Indicative assessment from public data using the published methodology factors; not a credit rating.

Registered office and contact

Registered office—

GSTIN—

Email—

Website—

Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of Bone Biologics Corp

Competitors10identified

Countries1most in United States

Top competitors by location

Company	Description	Domain	Founded	Location
Vertex Pharmaceuticals	Part of Vertex Pharmaceuticals.	vrtx.com	1991	United States
Moderna	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	modernatx.com	2018	United States
Becton Dickinson	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	bd.com	—	United States
Illumina	Part of Illumina.	illumina.com	2000	United States
Guardant Health	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	guardanthealth.com	2018	United States
Revvity Inc.	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	revvity.com	—	United States
Exelixis	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	exelixis.com	2000	United States
Neurocrine Biosciences	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	neurocrine.com	1996	United States
BioMarin Pharmaceutical	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	biomarin.com	1999	United States
Bio-Rad Laboratories	Biotechnology & Vaccines · Pharmaceuticals & Healthcare	bio-rad.com	1980	United States

Similar companies

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Business activities and related parties

Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.

Filings

No filings on record yet.